Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - granpidam
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp24658ce59b10f683d894acb365dd27b9
identifier: http://ema.europa.eu/identifier
/EU/1/16/1137/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Granpidam 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-24658ce59b10f683d894acb365dd27b9
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/16/1137/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - granpidam
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Granpidam contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. Granpidam brings down blood pressure in the lungs by widening the blood vessels in the lungs. Granpidam is used to treat adults and children and adolescents from 1 to 17 years old with high blood pressure in the blood vessels in the lungs (pulmonary arterial hypertension).
Do not take Granpidam
Warnings and precautions Talk to your doctor before taking Granpidam if you:
When used to treat male erectile dysfunction (ED), the following visual side effects have been reported with PDE5 inhibitors, including sildenafil at an unknown frequency; partial, sudden, temporary, or permanent decrease or loss of vision in one or both eyes.
If you experience sudden decrease or loss of vision, stop taking Granpidam and contact your doctor immediately (see also section 4).
Prolonged and sometimes painful erections have been reported in men after taking sildenafil. If you have an erection, which lasts continuously for more than 4 hours, stop taking Granpidam and contact your doctor immediately (see also section 4).
Special considerations for patients with kidney or liver problems You should tell your doctor if you have kidney or liver problems, as your dose may need to be adjusted.
Children Granpidam should not be given to children below 1 year of age.
Other medicines and Granpidam Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Medicines containing sacubitril/valsartan, used to treat heart failure.
Granpidam with food and drink You should not drink grapefruit juice while you are being treated with Granpidam.
Pregnancy and breast-feeding If you are pregnant, or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Granpidam should not be used during pregnancy unless strictly necessary. Granpidam should not be given to women of child bearing potential unless using appropriate contraceptive methods. Granpidam passes into your breast milk at very low levels and would not be expected to harm your baby.
Driving and using machines Granpidam can cause dizziness and can affect vision. You should be aware of how you react to the medicine before you drive or use machines.
Granpidam contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Granpidam contains sodium This medicine contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
For adults, the recommended dose is 20 mg three times a day (taken 6 to 8 hours apart) taken with or without food.
Use in children and adolescents For children and adolescents aged 1 year to 17 years old, the recommended dose is either 10 mg three times a day for children and adolescents 20 kg or 20 mg three times a day for children and adolescents >20 kg, taken with or without food. Higher doses should not be used in children. This medicine should be used only in case of administration of 20 mg three times a day. Other pharmaceutical forms may be more appropriate for administration to patients 20 kg and other younger patients who are not able to swallow tablets.
If you take more Granpidam than you should You should not take more medicine than your doctor tells you to. If you take more medicine than you have been told to take contact your doctor immediately. Taking more Granpidam than you should may increase the risk of known side effects.
If you forget to take Granpidam If you forget to take Granpidam, take a dose as soon as you remember, then continue to take your medicine at the usual times. Do not take a double dose to make up for a forgotten dose.
If you stop taking Granpidam Suddenly stopping your treatment with Granpidam may lead to your symptoms getting worse. Do not stop taking Granpidam unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects you should stop taking Granpidam and contact a doctor immediately (see also section 2):
Adults Side effects reported very commonly (may affect more than 1 in 10 people) were headache, facial flushing, indigestion, diarrhoea and pain in the arms or legs.
Side effects reported commonly (may affect up to 1 in 10 people) included: infection under the skin, flu-like symptoms, inflammation of the sinuses, reduced number of red blood cells (anaemia), fluid retention, difficulty sleeping, anxiety, migraine, shaking, pins and needles -like sensation, burning sensation, reduced sense of touch, bleeding at the back of the eye, effects on vision, blurred vision and light sensitivity, effects on colour vision, eye irritation, bloodshot eyes /red eyes, vertigo, bronchitis, nosebleed, runny nose, cough, stuffy nose, stomach inflammation, gastroenteritis, heartburn, piles, abdominal distension, dry mouth, hair loss, redness of the skin, night sweats, muscle aches, back pain and increased body temperature.
Side effects reported uncommonly (may affect 1 in 100 people) included: reduced sharpness of vision, double vision, abnormal sensation in the eye, penile bleeding, presence of blood in semen and/or urine, and breast enlargement in men.
Skin rash and sudden decrease or loss of hearing and decreased blood pressure have also been reported at an unknown frequency (frequency cannot be estimated from the available data).
Children and adolescents The following serious adverse events have been reported commonly (may affect up to 1 in 10 people); pneumonia, heart failure, right heart failure, heart related shock, high blood pressure in the lungs, chest pain, fainting, respiratory infection, bronchitis, viral infection in the stomach and intestines, urinary tract infections and tooth cavities.
The following serious adverse events were considered to be treatment related and were reported uncommonly (may affect up to 1 in 100 people), allergic reaction (such as skin rash, swelling of the face, lips and tongue, wheezing, difficulty breathing or swallowing), convulsion, irregular heart-beat, hearing impairment, shortness of breath, inflammation of the digestive tract, wheezing due to disrupted airflow.
Side effects reported very commonly (may affect more than 1 in 10 people) were headache, vomiting, infection of the throat, fever, diarrhoea, flu and nosebleed.
Side effects reported commonly (may affect up to 1 in 10 people) were nausea, increased erections, pneumonia and runny nose.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP . The expiry date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Granpidam contains
What Granpidam looks like and contents of the pack White to off white, round shaped, approximately 6.6 mm in diameter, biconvex, film-coated tablets, debossed with 20 on one side and plain on other side.
Granpidam 20 mg film-coated tablets are provided in PVC/Alu blister packs containing 90 tablets and 300 tablets. Granpidam 20 mg film-coated tablets are also provided in PVC/Alu perforated unit dose blister packs containing 15x1, 90x1 and 300x1 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Accord Healthcare S.L.U.
World Trade Center, Moll de Barcelona, s/n,
Edifici Est 6 planta,
08039 Barcelona,
Spain
Manufacturer Accord Healthcare B.V.,
Winthontlaan 200,
3526 KV Utrecht,
The Netherlands
or
Laboratori Fundaci DAU C/ C, 12-14 Pol. Ind. Zona Franca, 08040 Barcelona, Spain
or
Accord Healthcare Polska Sp.z o.o., ul. Lutomierska 50,95-200 Pabianice, Poland
This leaflet was last revised in 07/2Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Entry 1 - fullUrl = Composition/composition-en-24658ce59b10f683d894acb365dd27b9
Resource Composition:
Generated Narrative: Composition composition-en-24658ce59b10f683d894acb365dd27b9
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/16/1137/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - granpidam
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp24658ce59b10f683d894acb365dd27b9
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp24658ce59b10f683d894acb365dd27b9
identifier:
http://ema.europa.eu/identifier
/EU/1/16/1137/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Granpidam 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en